The current CGEM market cap is 1.22B. The company's latest EPS is USD -3.5565 and P/E is -7.96.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -29.77M | -32.61M | -62.76M | -37.61M | -45.24M |
Net Income | -24.8M | -26.78M | -57.96M | -32.21M | -39.18M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | 18.94M | 0 | 0 |
Operating Income | -22.27M | -60.34M | -67.95M | -132.14M | -191.09M |
Net Income | -20.66M | -51.8M | -65.57M | 111.21M | -153.16M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 617.24M | 561.12M | 514.99M | 521.98M | 494.71M |
Total Liabilities | 31.11M | 26.09M | 29.34M | 22.41M | 25.89M |
Total Equity | 586.13M | 535.03M | 485.65M | 499.57M | 468.82M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 100.46M | 214.71M | 437.19M | 561.12M | 484.18M |
Total Liabilities | 2.6M | 14.39M | 11.81M | 26.09M | 30.29M |
Total Equity | -39.91M | -76.34M | 425.37M | 535.03M | 453.9M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -101.68M | -126.66M | -51M | -82M | -116.14M |
Investing | 277.59M | 248.98M | 15.18M | 27.29M | -15.66M |
Financing | 6.98M | -25.93M | 1.79M | 40.39M | 40.5M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -20.9M | -29.77M | -43.43M | -126.66M | -134.33M |
Investing | -35.4M | -5.42M | -333.78M | 248.98M | 35.81M |
Financing | 85.72M | 140.14M | 268.78M | -25.93M | 40.75M |
Market Cap | 1.22B |
Price to Earnings Ratio | -7.96 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 12.39 |
Price to Book Ratio | 2.69 |
Dividend Yield | - |
Shares Outstanding | 43.07M |
Average Volume (1 week) | 2.26M |
Average Volume (1 Month) | 1.22M |
52 Week Change | 188.40% |
52 Week High | 29.25 |
52 Week Low | 7.64 |
Spread (Intraday) | 2.22 (7.35%) |
Company Name | Cullinan Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.cullinanoncology.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.